Cargando…
Patient treatment satisfaction after switching to NovoMix(®) 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
PURPOSE: Understanding treatment satisfaction (TS) for diabetes is increasingly important as treatment options increase. This study examines treatment satisfaction with NovoMix(®) 30 in an observational study in patients with type 2 diabetes. METHODS: The DiabMedSat assesses Overall, Treatment Burde...
Autores principales: | Brod, Meryl, Valensi, Paul, Shaban, Joseph A., Bushnell, Don M., Christensen, Torsten L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963740/ https://www.ncbi.nlm.nih.gov/pubmed/20602172 http://dx.doi.org/10.1007/s11136-010-9699-0 |
Ejemplares similares
-
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009) -
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009) -
Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
por: Shah, S, et al.
Publicado: (2009) -
Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement
por: Brito, Miguel, et al.
Publicado: (2011) -
Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis
por: Guo, Lixin, et al.
Publicado: (2021)